ReviewPituitary2022
Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.
Review in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of sex on mortality in patients with pituitary adenomas.Pituitary · 2026Review
- Crooke Cell Adenoma Presenting With Refractory Hypokalemia and Uncontrolled Hypertension.JCEM case reports · 2026Article
- Venous thromboembolism in Cushing syndrome: current evidence and a practical thromboprophylaxis algorithm.Frontiers in endocrinology · 2026Review
- Hypercoagulability in Cushing's syndrome: past, present, future.Archives of endocrinology and metabolism · 2025Review
- Thrombotic complications of glucocorticoids and anabolic steroids.Research and practice in thrombosis and haemostasis · 2025Review
- Article
- Article
- Cushing syndrome.Nature reviews. Disease primers · 2025Review
- Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.Endocrine reviews · 2025Review
- Can we predict the risk of venous thromboembolism in patients with Cushing's syndrome: a nationwide cohort analysis.Pituitary · 2024Article
- Cushing's syndrome and COVID-19.Pituitary · 2024Review
- Hypercoagulable state and risk of venous thromboembolism in Cushing syndrome.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
- Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey.Endocrine connections · 2024Article
- Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess.Current vascular pharmacology · 2024Review
- An individualized approach to the management of Cushing disease.Nature reviews. Endocrinology · 2023Review
- Preoperative management of patients with ectopic Cushing's syndrome caused by ACTH-secreting pheochromocytoma: a case series and review of the literature.Journal of endocrinological investigation · 2023Review
- Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.The Journal of clinical endocrinology and metabolism · 2023Article
- Pregnancy complicated with adrenal adenoma causing ACTH-independent Cushing's syndrome, accompanied by obstetric antiphospholipid syndrome and severe pre-eclampsia: case report and literature review.Frontiers in endocrinology · 2023Review
- Special issue: Cushing's disease update.Pituitary · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Cushing's syndrome (CS) is associated with a hypercoagulable state resulting in an increased risk on venous thromboembolism (VTE). In patients with untreated active CS VTE incidence is up to 18-fold higher compared to the general population, whereas after pituitary and adrenal surgery a postoperative VTE risk between 2.6 and 5.6% has been reported. Interestingly, after surgery the VTE risk is not only increased in the first week but also during several months postoperatively. The hypercoagulable state in CS is thought to be caused, at least in part, by an imbalance between activity of pro- and anticoagulant pathways. However, changes in activated partial thromboplastin time and plasma concentrations of pro-and anticoagulant factors are not observed in every CS patient. Only retrospective studies have shown that thromboprophylaxis lowers VTE risk in CS. Future prospective studies should asses the optimal timing, duration and type of thromboprophylaxis in CS to improve VTE-related morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.